Peptilogics is developing engineered peptide medicines to address difficult medical device-related bacterial infections. Its lead investigational candidate, zaloganan (PLG0206), targets bacterial biofilms, with an initial focus on infections involving prosthetic joints. The Pittsburgh company was founded by Jonathan Steckbeck. [1] [2]
In March 2026, Peptilogics began enrolling patients in RETAIN, a randomized Phase 2/3 trial evaluating PLG0206 during surgery for infections following total knee replacement. A $78 million Series B2 financing announced in October 2025 supports pivotal development of the program. [3] [4]